Adding Nivolumab to SABR Improves EFS in NSCLC

Adding nivolumab to treatment with SABR improved the 4-year event-free survival rate in a phase 2 trial of patients with NSCLC.

Related Keywords

Houston ,Texas ,United States ,Bristol Myers Squibb ,Joey Chang ,University Of Texas Md Anderson Cancer Center ,Cancer Center ,